Navigation Links
Enbrel® (etanercept) Patent Issued
Date:11/22/2011

THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today issued the following statement:

Amgen today announced  the issuance of U.S. Patent No. 8,063,182 related to Enbrel® (etanercept).  This patent is owned by Hoffman-La Roche Inc. ("Roche") and exclusively licensed to Amgen. Immunex Corporation (acquired by Amgen in 2002) originally licensed this patent application from Roche in 1999, and in 2004, Amgen paid Roche a one-time payment and obtained an exclusive, fully paid-up license to the application which issued today as the '182  patent.  The patent describes and claims the fusion protein that is etanercept, and by statute, the '182 patent has a term of 17 years from today.

About ENBREL
ENBREL is a soluble form of a fully human tumor necrosis factor (TNF) receptor with a clinical efficacy and safety profile established over 18 years of collective clinical experience. ENBREL was first approved in the U.S. in 1998 for moderate to severe rheumatoid arthritis and was later approved to treat children and adolescents with moderate to severe juvenile rheumatoid arthritis (now called juvenile idiopathic arthritis) in 1999. In 2004, ENBREL was approved in the U.S. to treat adult chronic moderate to severe plaque psoriasis. Prescription ENBREL is given by injection.

ENBREL indications in the U.S.:

  • ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
  • ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.
  • ENBREL is indicated for reducing signs and symptoms,
    '/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease
2. Epitomics, Inc. Receives Notice of Allowance from the United States Patent and Trademark Office for a Novel Method for Identifying Differentially Expressed Proteins
3. iBio Announces New US Patent for iBioLaunch™ Technology
4. NuMe Health Advances its Cobiotics™ Technology With Addition of Scientific Advisory Board and Filing of Patent Application for First Product
5. Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
6. KGI Professor Awarded Patent for Stem-Cell Therapy Aiding Heart-attack Patients
7. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
8. Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations
9. Life Technologies Applauds Signing of Patent Reform Bill
10. MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices
11. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ... new report "Neuroprotection - Drugs, Markets and ... report describes the role of neuroprotection in acute ... nervous system as well as in chronic diseases ... underlying mechanisms of damage to neural tissues are ...
(Date:5/28/2015)... DryLet, LLC a biotechnology company providing ... animal waste reduction, bioremediation, wastewater treatment, aquaculture and ... plants and restaurant kitchen settings, announced today it ... 3-5 in Des Moines, Iowa. , ManureMagic™ was ... Journal article because of its industry-leading qualities and ...
(Date:5/28/2015)... 28, 2015 Biscayne Pharmaceuticals, Inc ., ... its growth hormone-releasing hormone (GHRH) technology will be discussed in ... Annual Meeting. The data show that the family of ... blockers, is present on many primary breast cancer cells ... GHRH antagonists could have broad anti-cancer potential in breast ...
(Date:5/28/2015)... Sunnyvale, Californiaa (PRWEB) May 28, 2015 ... on “ The Changing Landscape of EMR/EHR Clinical Data ... Annual Meeting taking place in Washington, DC on June ... the challenges of integrating EMR/EHR systems with EDC, and ... the opportunities brought by eSource and electronic health records/electronic ...
Breaking Biology Technology:Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3DryLet to Showcase Patented ManureMagic™ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2
... March 31, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: ... developer, manufacturer and distributor of probiotics products in China, ... sales order from its newly signed U.S. customer. ... first sales order, and formally entered into its agreement ...
... the genome engineering specialist, has announced its consolidated financial results ... Main financial items : ... 2010, from EUR 10.1M to EUR 15.8M. Growth was ... as a result of several major contracts (Boehringer Ingelheim, Bayer ...
... and US, including researchers at Arizona State University, have ... a means of producing renewable fuel. This award ... Assistant Professor Anne Jones in the department of chemistry ... efficiency of photosynthesis. This will lead to ways of ...
Cached Biology Technology:China-Biotics Receives First U.S. Sales Order 2China-Biotics Receives First U.S. Sales Order 3Cellectis Publishes 2010 Financial Results 2Cellectis Publishes 2010 Financial Results 3Cellectis Publishes 2010 Financial Results 4Cellectis Publishes 2010 Financial Results 5Biological nanowires expedite future fuel production 2
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... the Midlands Consortium say they are absolutely delighted ... chosen to host a new 1billion national institute ... is comprised of the universities of Birmingham, Loughborough ... extensive and complementary energy related research activities. ...
... on September 27 and 28, when male contraception researchers from ... The second Future of Male Contraception conference sponsored by ... the World Health Organization, and the University of Washington ... Registration is free of charge. Here is a ...
... and Ali Saib are joint winners of the 2007 ... recipients present science in a unique format that is ... the award. Using different media, they have produced resources ... science to the broader community. Professor Ali Saib ...
Cached Biology News:Midlands Consortium delighted to be chosen to host £1 billion energy institute 2Midlands Consortium delighted to be chosen to host £1 billion energy institute 32 French scientists win European award for communication 22 French scientists win European award for communication 3
Sufficient reagents for 50 applications.Mitochondria Isolation Kit Reagent A, 50 ml Mitochondria Isolation Kit Reagent B, 500 l Mitochondria Isolation Kit Reagent C, 70 ml...
... cassette is designed to allow ampicillin selection ... gb2 driving the gene for ampicillin resistance ... Em7 promoter. It mediates higher transcription efficiency ... synthetic polyadenylation signal terminates the ampicillin expression. ...
... can be difficult to achieve in many ... one or more restriction and modification (R-M) ... recognized as "foreign". TypeOne™ Restriction Inhibitor provides ... in bacterial strains with type I R-M ...
... Y is most widely used in ... and differentially stain nucleic acids following ... dye solution, Pyronin Y stains RNA ... green. Chem comp: Dye ...
Biology Products: